Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.74
XOMA's Cash to Debt is ranked lower than
83% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. XOMA: 0.74 )
Ranked among companies with meaningful Cash to Debt only.
XOMA' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1 Max: No Debt
Current: 0.74
Equity to Asset -0.53
XOMA's Equity to Asset is ranked lower than
95% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. XOMA: -0.53 )
Ranked among companies with meaningful Equity to Asset only.
XOMA' s Equity to Asset Range Over the Past 10 Years
Min: -0.77  Med: -0.02 Max: 0.78
Current: -0.53
-0.77
0.78
F-Score: 3
Z-Score: -39.27
M-Score: -2.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -49.29
XOMA's Operating margin (%) is ranked higher than
56% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. XOMA: -49.29 )
Ranked among companies with meaningful Operating margin (%) only.
XOMA' s Operating margin (%) Range Over the Past 10 Years
Min: -433.75  Med: -104.78 Max: 13.17
Current: -49.29
-433.75
13.17
Net-margin (%) 2.46
XOMA's Net-margin (%) is ranked higher than
73% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. XOMA: 2.46 )
Ranked among companies with meaningful Net-margin (%) only.
XOMA' s Net-margin (%) Range Over the Past 10 Years
Min: -349.94  Med: -121.15 Max: 2.46
Current: 2.46
-349.94
2.46
ROA (%) 2.20
XOMA's ROA (%) is ranked higher than
80% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. XOMA: 2.20 )
Ranked among companies with meaningful ROA (%) only.
XOMA' s ROA (%) Range Over the Past 10 Years
Min: -108.21  Med: -51.27 Max: 2.2
Current: 2.2
-108.21
2.2
ROC (Joel Greenblatt) (%) 194.99
XOMA's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. XOMA: 194.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XOMA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1636.29  Med: -304.24 Max: 194.99
Current: 194.99
-1636.29
194.99
Revenue Growth (3Y)(%) -3.40
XOMA's Revenue Growth (3Y)(%) is ranked lower than
58% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. XOMA: -3.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XOMA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.8  Med: -21.3 Max: 147.9
Current: -3.4
-60.8
147.9
EBITDA Growth (3Y)(%) -49.30
XOMA's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. XOMA: -49.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XOMA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.3  Med: -21.4 Max: 31.1
Current: -49.3
-49.3
31.1
EPS Growth (3Y)(%) -46.30
XOMA's EPS Growth (3Y)(%) is ranked lower than
89% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. XOMA: -46.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XOMA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.4  Med: -13.6 Max: 35
Current: -46.3
-52.4
35
» XOMA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

XOMA Guru Trades in Q3 2015

Paul Tudor Jones 64,225 sh (New)
Jim Simons Sold Out
» More
Q4 2015

XOMA Guru Trades in Q4 2015

Paul Tudor Jones 45,125 sh (-29.74%)
» More
Q1 2016

XOMA Guru Trades in Q1 2016

Paul Tudor Jones 30,766 sh (-31.82%)
» More
Q2 2016

XOMA Guru Trades in Q2 2016

Joel Greenblatt 13,497 sh (New)
Jim Simons 461,220 sh (New)
Paul Tudor Jones 30,730 sh (-0.12%)
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:CVM, NAS:PIRS, NAS:DRNA, OTCPK:CWBR, NAS:NTEC, NAS:DMPI, NAS:AUPH, NAS:LIFE, OTCPK:MCUJF, NAS:ALDX, NAS:ADMA, NAS:MBRX, NAS:KMPH, NAS:TENX, NAS:AVEO, NAS:MTP, NAS:THLD, OTCPK:INNMF, NAS:QLTI, OTCPK:HSDT » details
Traded in other countries:X0M.Germany,
XOMA Corp discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites.

XOMA Corp was incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. The Company discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites. The compounds are designed to either enhance or diminish the protein's activity as desired. Its lead product candidate, gevokizumab, is a proprietary potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). It is also developing XOMA 3AB, a combination, or cocktail, of antibodies designed to neutralize the most potent of botulinum toxins. Its geographic segments include United States, Europe, and Asia Pacific. The Company's competitors include AbbVie Inc., Biovitrum AB, Allergan, Novartis AG, pSivida, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Emergent BioSolutions, Inc. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of any future products.

Ratios

vs
industry
vs
history
P/E(ttm) 29.50
XOMA's P/E(ttm) is ranked higher than
50% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 28.85 vs. XOMA: 29.50 )
Ranked among companies with meaningful P/E(ttm) only.
XOMA' s P/E(ttm) Range Over the Past 10 Years
Min: 11.54  Med: 23.55 Max: 41.88
Current: 29.5
11.54
41.88
PE(NRI) 29.50
XOMA's PE(NRI) is ranked lower than
51% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. XOMA: 29.50 )
Ranked among companies with meaningful PE(NRI) only.
XOMA' s PE(NRI) Range Over the Past 10 Years
Min: 11.59  Med: 23.58 Max: 41.88
Current: 29.5
11.59
41.88
Price/Owner Earnings (ttm) 42.14
XOMA's Price/Owner Earnings (ttm) is ranked lower than
54% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 30.57 vs. XOMA: 42.14 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
XOMA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 31.48  Med: 38.64 Max: 47.86
Current: 42.14
31.48
47.86
P/S 1.27
XOMA's P/S is ranked higher than
93% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. XOMA: 1.27 )
Ranked among companies with meaningful P/S only.
XOMA' s P/S Range Over the Past 10 Years
Min: 0.55  Med: 4.44 Max: 36.88
Current: 1.27
0.55
36.88
EV-to-EBIT 15.31
XOMA's EV-to-EBIT is ranked higher than
65% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 23.94 vs. XOMA: 15.31 )
Ranked among companies with meaningful EV-to-EBIT only.
XOMA' s EV-to-EBIT Range Over the Past 10 Years
Min: -674.5  Med: -4.95 Max: 17.1
Current: 15.31
-674.5
17.1
EV-to-EBITDA 12.84
XOMA's EV-to-EBITDA is ranked higher than
67% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 19.79 vs. XOMA: 12.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
XOMA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.9  Med: -4.4 Max: 233
Current: 12.84
-58.9
233
Current Ratio 1.50
XOMA's Current Ratio is ranked lower than
82% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. XOMA: 1.50 )
Ranked among companies with meaningful Current Ratio only.
XOMA' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 3.03 Max: 6.65
Current: 1.5
0.63
6.65
Quick Ratio 1.50
XOMA's Quick Ratio is ranked lower than
77% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. XOMA: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
XOMA' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 3.03 Max: 6.65
Current: 1.5
0.63
6.65
Days Sales Outstanding 6.40
XOMA's Days Sales Outstanding is ranked higher than
90% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. XOMA: 6.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
XOMA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.4  Med: 66.02 Max: 226.37
Current: 6.4
6.4
226.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.00
XOMA's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. XOMA: -13.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XOMA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -82.6  Med: -15.4 Max: -6.3
Current: -13
-82.6
-6.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.29
XOMA's Price/Median PS Value is ranked higher than
90% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. XOMA: 0.29 )
Ranked among companies with meaningful Price/Median PS Value only.
XOMA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 2.53 Max: 63.18
Current: 0.29
0.14
63.18
Earnings Yield (Greenblatt) (%) 6.50
XOMA's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. XOMA: 6.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XOMA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.8  Med: 11 Max: 19.6
Current: 6.5
5.8
19.6

More Statistics

Revenue (TTM) (Mil) $54.66
EPS (TTM) $ 0.02
Beta2.28
Short Percentage of Float7.72%
52-Week Range $0.44 - 2.03
Shares Outstanding (Mil)120.58

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 7 5 5
EPS ($) -0.47 -0.53 -0.53
EPS w/o NRI ($) -0.47 -0.53 -0.53
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
XOMA Ltd. Reports Operating Results (10-K) Mar 10 2011 
XOMA Ltd. Reports Operating Results (10-K/A) Dec 27 2010 
XOMA Ltd. Reports Operating Results (10-Q/A) Nov 12 2010 
XOMA Ltd. Reports Operating Results (10-Q) May 06 2010 
XOMA Ltd. Reports Operating Results (10-Q) Aug 06 2009 
XOMA Ltd. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
XOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference Aug 11 2016
ETF’s with exposure to XOMA Corp. : August 11, 2016 Aug 11 2016
XOMA CORP Financials Aug 11 2016
XOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 Aug 09 2016
Xoma reports 2Q loss Aug 03 2016
Xoma reports 2Q loss Aug 03 2016
XOMA Reports Second Quarter 2016 Achievements and Financial Results Aug 03 2016
XOMA CORP Files SEC form 10-Q, Quarterly Report Aug 03 2016
XOMA Reports Second Quarter 2016 Achievements and Financial Results Aug 03 2016
XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital... Jul 20 2016
XOMA to Present at the Cantor Fitzgerald Healthcare Conference Jul 05 2016
XOMA to Present at the Cantor Fitzgerald Healthcare Conference Jul 05 2016
XOMA Initiates Phase 2 Proof-of-Concept Study of XOMA 213 Jun 28 2016
XOMA Initiates Phase 2 Proof-of-Concept Study of XOMA 213 Jun 28 2016
ETF’s with exposure to XOMA Corp. : June 20, 2016 Jun 20 2016
Biotech Industrys Stocks Get Research Review Jun 03 2016
XOMA to Present at the Jefferies Global Healthcare Conference Jun 02 2016
XOMA to Present at the Jefferies Global Healthcare Conference Jun 02 2016
XOMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... May 23 2016
ETF’s with exposure to XOMA Corp. : May 20, 2016 May 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)